Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock?

View original at finance.yahoo.com
Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock? Wells Fargo & Company WFC is slated to report first-quarter 2026 earnings results on April 14, 2026, before market open…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wells Fargo has outpaced earnings consensus estimates in the trailing four quarters with average surprise of 7.53%

    60% confidence

  • Mortgage banking revenues expected to be $283 million in Q1 2026, suggesting 14.8% decline from year-ago level

    60% confidence

  • Net interest income expected to be $12.3 billion in Q1 2026, indicating 6.9% rise from year-ago quarter

    60% confidence

  • Wells Fargo Q1 2026 revenues expected to reach $21.73 billion, representing 7.8% year-over-year growth

    60% confidence

  • Demand for commercial and industrial and consumer loans was impressive in the first two months of Q1 2026, while real estate loan demand was subdued

    60% confidence

  • Investment advisory and other asset-based fee revenues expected to be $2.9 billion in Q1 2026, indicating 12.8% year-over-year rise

    60% confidence

  • Wells Fargo Q1 2026 earnings per share expected to be $1.57, representing 23.6% improvement from prior-year quarter

    60% confidence

Data points we hold from this source

Wells Fargo & Company · mortgage banking revenues283 USD
Wells Fargo & Company · investment advisory fee growth12.8 percent
Wells Fargo & Company · net interest income growth6.9 percent
Wells Fargo & Company · investment advisory fees2.9 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com